##ANALYSISTYPE=SOMATIC_PAIR
##PIPELINE=megSAP 0.2-296-g569671f
##FILTER=all-unknown=Allele unknown
##FILTER=depth-nor=Sequencing depth in normal is too low (< 20)
##FILTER=depth-tum=Sequencing depth in tumor is too low (< 20)
##FILTER=freq-nor=Allele frequency in normal > 0.17 * allele frequency in tumor
##FILTER=freq-tum=Allele frequency in tumor < 0.05
##FILTER=LowDepth=Tumor or normal sample read depth at this locus is below 2
##FILTER=LowEVS=Somatic Empirical Variant Score (SomaticEVS) is below threshold
##FILTER=lt-3-reads=Less than 3 supporting tumor reads
##FILTER=off-target=Variant marked as 'off-target'.
##FILTER=special-chromosome=Special chromosome
##SAMPLE=<ID=GS110168_03,Gender=n/a,ExternalSampleName=SL-ALL-1; Pat7;QA007004DQ,IsTumor=yes,IsFFPE=no,DiseaseGroup=Neoplasms,DiseaseStatus=Affected>
##SAMPLE=<ID=GS110169_03,Gender=n/a,ExternalSampleName=SL-FB-1; Pat7;QA007011D9,IsTumor=no,IsFFPE=no,DiseaseGroup=Neoplasms,DiseaseStatus=Affected>
##DESCRIPTION=filter=Annotations for filtering and ranking variants.
##DESCRIPTION=quality=Quality parameters - variant quality (QUAL), depth (DP), allele frequency (AF), mean mapping quality of alternate allele (MQM), probability of strand bias for alternate bases as phred score (SAP), probability of allele ballance as phred score (ABP)
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, ENST number, type, impact, exon/intron number, HGVS.c, HGVS.p, Pfam domain).
##DESCRIPTION=coding_and_splicing_refseq=Coding and splicing details based on RefSeq (Gene, RefSeq id, type, impact, exon/intron number, HGVS.c, HGVS.p, Pfam domain).
##DESCRIPTION=regulatory=Regulatory consequence details.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=1000g=Allele frequency in 1000 genomes project.
##DESCRIPTION=gnomAD=Allele frequency in gnomAD project.
##DESCRIPTION=gnomAD_hom_hemi=Homoyzgous counts and hemizygous counts of gnomAD project (genome data).
##DESCRIPTION=gnomAD_sub=Sub-population allele frequenciens (AFR,AMR,EAS,NFE,SAS) in gnomAD project.
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=Sift=Sift effect prediction and score for each transcript: D=damaging, T=tolerated.
##DESCRIPTION=PolyPhen=PolyPhen (humVar) effect prediction and score for each transcript: D=probably damaging, P=possibly damaging, B=benign.
##DESCRIPTION=fathmm-MKL=fathmm-MKL score (for coding/non-coding regions). Deleterious threshold > 0.5.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 10-20.
##DESCRIPTION=REVEL=REVEL pathogenicity prediction score. Deleterious threshold > 0.5.
##DESCRIPTION=MaxEntScan=MaxEntScan splicing prediction (reference bases score/alternate bases score).
##DESCRIPTION=dbscSNV=dbscSNV splicing prediction (ADA/RF score).
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##DESCRIPTION=MMSplice_DeltaLogitPSI=MMsplice delta Logit PSI score: variant's effect on the exon inclusion - positive score shows higher exon inclusion, negative higher exclusion rate. A score greater than 2 or less than -2 can be considered strong.
##DESCRIPTION=MMSplice_pathogenicity=MMsplice pathogenicity score: probability of pathogenic effect of the variant on splicing
##DESCRIPTION=SpliceAI=SpliceAI prediction of splice-site variations. Probability of the variant being splice-altering (range from 0-1). The score is the maximum value of acceptor/donor gain/loss of all effected genes.
##DESCRIPTION=NGSD_som_c=Somatic variant count in the NGSD.
##DESCRIPTION=NGSD_som_p=Project names of project containing this somatic variant in the NGSD.
##DESCRIPTION=NGSD_som_vicc_interpretation=Somatic variant interpretation according VICC standard in the NGSD.
##DESCRIPTION=NGSD_som_vicc_comment=Somatic VICC interpretation comment in the NGSD.
##DESCRIPTION=NGSD_hom=Homozygous variant count in NGSD.
##DESCRIPTION=NGSD_het=Heterozygous variant count in NGSD.
##DESCRIPTION=NGSD_group=Homozygous / heterozygous variant count in NGSD with the same disease group.
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validation=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Variant comments from the NGSD.
##DESCRIPTION=gene_info=Gene information from NGSD (inheritance mode, gnomAD o/e scores).
##DESCRIPTION=CMC_genes=Gene symbol from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_MUTATION_ID=COSV identifier of variant from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_disease=diseases with > 1% of samples mutated where disease = Primary site(tissue) / Primary histology / Sub-histology = Samples mutated / Samples tested = Frequency from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_DNDS_ratio=diseases with significant dn/ds ratio (q-value < 5%) from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_mutation_significance=Significance tier of the variant from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CANCERHOTSPOTS_AA_CHANGE=Amino acid change as in original cancerhotspots.org file
##DESCRIPTION=CANCERHOTSPOTS_TOTAL_MUT=Total mutation count in cancerhotspots.org at certain amino acid position.
##DESCRIPTION=CANCERHOTSPOTS_ALT_COUNT=Count of specific amino acid alteration at same position in cancerhotspots.org.
##DESCRIPTION=tumor_af=Mutant allele frequency in tumor (Sample GS110168_03).
##DESCRIPTION=tumor_dp=Tumor Depth (Sample GS110168_03).
##DESCRIPTION=normal_af=Mutant allele frequency in normal (Sample GS110169_03).
##DESCRIPTION=normal_dp=Normal depth (Sample GS110169_03).
##DESCRIPTION=somatic_classification_comment=Somatic classification comment from the NGSD.
##DESCRIPTION=somatic_classification=Somatic classification from the NGSD.
#chr	start	end	ref	obs	tumor_af	tumor_dp	normal_af	normal_dp	filter	quality	gene	variant_type	coding_and_splicing	coding_and_splicing_refseq	regulatory	OMIM	ClinVar	HGMD	RepeatMasker	dbSNP	1000g	gnomAD	gnomAD_hom_hemi	gnomAD_sub	phyloP	Sift	PolyPhen	fathmm-MKL	CADD	REVEL	MaxEntScan	dbscSNV	COSMIC	MMSplice_DeltaLogitPSI	MMSplice_pathogenicity	SpliceAI	NGSD_som_c	NGSD_som_p	NGSD_som_vicc_interpretation	NGSD_som_vicc_comment	NGSD_hom	NGSD_het	NGSD_group	classification	classification_comment	somatic_classification	somatic_classification_comment	validation	comment	gene_info	CMC_genes	CMC_MUTATION_ID	CMC_disease	CMC_DNDS_ratio	CMC_mutation_significance	CANCERHOTSPOTS_AA_CHANGE	CANCERHOTSPOTS_TOTAL_MUT	CANCERHOTSPOTS_ALT_COUNT
chr10	70482262	70482262	A	G	0.1975	1209	0.0000	670		QUAL=567	CCAR1	start_lost	CCAR1:ENST00000265872:start_lost:HIGH:exon2/25:c.1A>G:p.Met1?:,CCAR1:ENST00000535016:start_lost:HIGH:exon2/24:c.1A>G:p.Met1?:,CCAR1:ENST00000543719:start_lost:HIGH:exon2/24:c.1A>G:p.Met1?:	CCAR1:NM_001282959.2:start_lost:HIGH:exon2/24:c.1A>G:p.Met1?:,CCAR1:NM_001282960.2:start_lost:HIGH:exon2/24:c.1A>G:p.Met1?:,CCAR1:NM_018237.4:start_lost:HIGH:exon2/25:c.1A>G:p.Met1?:,CCAR1:NR_104262.2:non_coding_transcript_exon_variant:MODIFIER:exon2/24:n.101A>G::	regulatory_region_variant:promoter										7.3930	D(0.01),D(0.01),D(0.01)	B(0.35),P(0.56),P(0.56)	0.92,0.95	23.40				COSV56269920				0				0	0	0 / 0							CCAR1 (inh=n/a oe_syn=0.86 oe_mis=0.58 oe_lof=0.12)								
chr14	105246551	105246551	C	T	0.4225	1114	0.0007	1359		QUAL=1948	AKT1	missense&splice_region	AKT1:ENST00000349310:missense_variant&splice_region_variant:MODERATE:exon4/15:c.49G>A:p.Glu17Lys:PF00169 [PH domain],AKT1:ENST00000402615:missense_variant&splice_region_variant:MODERATE:exon3/14:c.49G>A:p.Glu17Lys:PF00169 [PH domain],AKT1:ENST00000407796:missense_variant&splice_region_variant:MODERATE:exon3/14:c.49G>A:p.Glu17Lys:PF00169 [PH domain],AKT1:ENST00000554581:missense_variant&splice_region_variant:MODERATE:exon2/13:c.49G>A:p.Glu17Lys:PF00169 [PH domain],AKT1:ENST00000554848:missense_variant&splice_region_variant:MODERATE:exon3/14:c.49G>A:p.Glu17Lys:PF00169 [PH domain],AKT1:ENST00000555528:missense_variant&splice_region_variant:MODERATE:exon3/14:c.49G>A:p.Glu17Lys:PF00169 [PH domain]	AKT1:NM_001014431.2:missense_variant&splice_region_variant:MODERATE:exon3/14:c.49G>A:p.Glu17Lys:,AKT1:NM_001014432.1:missense_variant&splice_region_variant:MODERATE:exon4/15:c.49G>A:p.Glu17Lys:,AKT1:NM_005163.2:missense_variant&splice_region_variant:MODERATE:exon3/14:c.49G>A:p.Glu17Lys:		164730 [GENE=AKT1 PHENOS=Breast cancer,somatic,114480/Cowden syndrome 6,615109/Proteus syndrome,somatic,176920/Ovarian cancer,somatic,167000/Colorectal cancer,somatic,114500];	13983 [uncertain significance DISEASE=Hepatocellular carcinoma,Osteosarcoma,Transitional cell carcinoma of the bladder,Lung adenocarcinoma,Small cell lung cancer,Non-small cell lung cancer,Squamous cell lung carcinoma,Neoplasm of the breast,Neoplasm of the thyroid gland,Neoplasm of ovary,Prostate neoplasm,Neoplasm of the large intestine,Squamous cell carcinoma of the head and neck,Malignant melanoma of skin,Uterine cervical neoplasms,Meningeal Neoplasms,Adenocarcinoma of prostate,Carcinoma of colon,Proteus syndrome,Adenocarcinoma of stomach,Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation,Breast adenocarcinoma,Cowden syndrome 6];	CM1611160 [CLASS=DM MUT=ALT PHEN="Epidermal naevus with underlying overgrowth" GENE=AKT1];		rs121434592		0.0001		0.0000,0.0000,0.0000,0.0001,0.0000	7.3500	D(0.00),D(0.00),D(0.00),D(0.00),D(0.00),D(0.00)	D(1.00),D(1.00),D(1.00),D(1.00),D(1.00),D(1.00)	1.00,0.99	25.60	0.51	4.02>4.30		COSV62571334,COSV62576849				9	SomaticAndTreatment			0	0	0 / 0								AKT1	COSV62571334	breast/carcinoma/NS=61/3743=1.63%;bone/Overgrowth_syndrome/Proteus_syndrome=14/20=70%;thyroid/carcinoma/anaplastic_carcinoma=12/642=1.87%;meninges/meningioma/meningothelial=17/325=5.23%;NS/carcinoma/of_unknown_primary=4/209=1.91%;soft_tissue/desmoid_tumour-fibromatosis/NS=8/256=3.13%;breast/carcinoma/hormone_receptor-positive_carcinoma=9/328=2.74%;meninges/meningioma/transitional=5/259=1.93%;soft_tissue/Overgrowth_syndrome/Proteus_syndrome=7/10=70%;skin/Overgrowth_syndrome/Proteus_syndrome=51/60=85%;breast/carcinoma/luminal_A_carcinoma=4/58=6.9%;breast/carcinoma/ER-positive_carcinoma=57/1470=3.88%;breast/carcinoma/ER-PR-positive_carcinoma=17/364=4.67%;breast/carcinoma/ductal_carcinoma=114/3743=3.05%;prostate/carcinoma/NS=12/1135=1.06%;urinary_tract/carcinoma/transitional_cell_carcinoma=17/1082=1.57%;breast/carcinoma/lobular_carcinoma=26/503=5.17%;breast/carcinoma/basal_(triple-negative)_carcinoma=7/553=1.27%;endometrium/carcinoma/endometrioid_carcinoma=26/954=2.73%;meninges/meningioma/NS=40/427=9.37%	colon=0.0004;thyroid=0.0494;breast=5.59e-47;endometrioid=3.59e-15	1	ENST00000349310:p.Glu17Lys	149	148
chr21	10971453	10971453	T	C	0.3333	18	0.0000	10	depth-tum;depth-nor;off-target	QUAL=18	TPTE	intron	TPTE:ENST00000298232:intron_variant:MODIFIER:intron4/22:c.12-108A>G::,TPTE:ENST00000342420:intron_variant:MODIFIER:intron4/21:c.12-108A>G::,TPTE:ENST00000361285:intron_variant:MODIFIER:intron4/23:c.12-108A>G::	TPTE:NM_001290224.1:intron_variant:MODIFIER:intron3/18:c.-182+13592A>G::,TPTE:NM_199259.3:intron_variant:MODIFIER:intron4/22:c.12-108A>G::,TPTE:NM_199260.3:intron_variant:MODIFIER:intron4/21:c.12-108A>G::,TPTE:NM_199261.3:intron_variant:MODIFIER:intron4/23:c.12-108A>G::						rs1739180		0.3091	0,.		-0.2030			0.00,0.08	3.31								2	I17R006,eMed-HCC			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							TPTE (inh=n/a oe_syn=1.04 oe_mis=1.24 oe_lof=1.09)								
chr21	11039394	11039394	C	T	0.1739	46	0.0286	35	off-target	QUAL=44	BAGE2	non_coding_transcript_exon	BAGE2:ENST00000470054:non_coding_transcript_exon_variant:MODIFIER:exon6/10:n.810G>A::	BAGE2:NM_182482.2:3_prime_UTR_variant:MODIFIER:exon6/10:c.*272G>A::						rs2698623					-1.2040			0.03,0.54	9.02								0				0	1393	0 / 68							BAGE2 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)								
chr21	31744239	31744239	C	A	0.4340	106	0.0000	104		QUAL=216	KRTAP13-2	missense	KRTAP13-2:ENST00000399889:missense_variant:MODERATE:exon1/1:c.293G>T:p.Gly98Val:PF05287 [PMG protein]	KRTAP13-2:NM_181621.4:missense_variant:MODERATE:exon1/1:c.293G>T:p.Gly98Val:											0.3750	T(0.06)	B(0.30)	0.06,0.19	16.55	0.14							1	Leuk			0	0	0 / 0			inactivating	I am an inactivating variant class			KRTAP13-2 (inh=n/a oe_syn=1.28 oe_mis=1.23 oe_lof=1.71), MIR4327 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)								
chr21	33974094	33974094	-	T	1.0000	3	0.0000	9	depth-tum;depth-nor;off-target	QUAL=4	CFAP298,AP000275.65	3'UTR,intron	CFAP298:ENST00000290155:3_prime_UTR_variant:MODIFIER:exon7/7:c.*78dup::,CFAP298:ENST00000382549:3_prime_UTR_variant:MODIFIER:exon5/5:c.*1304dup::,AP000275.65:ENST00000553001:intron_variant:MODIFIER:intron5/6:c.666+1376dup::	C21orf59:NM_001350334.2:3_prime_UTR_variant:MODIFIER:exon6/6:c.*78dup::,C21orf59:NM_001350335.1:3_prime_UTR_variant:MODIFIER:exon5/5:c.*1304dup::,C21orf59:NM_001350336.2:3_prime_UTR_variant:MODIFIER:exon6/6:c.*78dup::,C21orf59:NM_001350337.2:3_prime_UTR_variant:MODIFIER:exon6/6:c.*439dup::,C21orf59-TCP10L:NM_001350338.2:intron_variant:MODIFIER:intron5/7:c.666+1376dup::,C21orf59:NM_021254.4:3_prime_UTR_variant:MODIFIER:exon7/7:c.*78dup::,C21orf59-TCP10L:NR_146638.2:intron_variant&non_coding_transcript_variant:MODIFIER:intron5/10:n.800+1376dup::,C21orf59-TCP10L:NR_146639.2:intron_variant&non_coding_transcript_variant:MODIFIER:intron5/11:n.800+1376dup::		615494 [GENE=CFAP298 PHENOS=Ciliary dyskinesia,primary,26,615500,Autosomal recessive];				rs79380292		0.0030	0,.						0.64								1	eMed-HCC			0	5	0 / 1							CFAP298 (inh=AR oe_syn=1.16 oe_mis=0.92 oe_lof=0.65)								
chr21	47737850	47737850	G	T	0.7857	14	0.0000	6	depth-tum;depth-nor;off-target	QUAL=18	C21orf58	intron	C21orf58:ENST00000291691:intron_variant:MODIFIER:intron2/7:c.309+76C>A::,C21orf58:ENST00000397679:intron_variant:MODIFIER:intron1/6:c.-259+76C>A::,C21orf58:ENST00000397680:intron_variant:MODIFIER:intron2/7:c.-179+76C>A::,C21orf58:ENST00000397682:intron_variant:MODIFIER:intron2/8:c.-259+76C>A::,C21orf58:ENST00000397683:intron_variant:MODIFIER:intron2/8:c.-259+76C>A::,C21orf58:ENST00000397685:intron_variant:MODIFIER:intron3/5:c.60+76C>A::	C21orf58:NM_001286462.1:intron_variant:MODIFIER:intron2/8:c.-259+76C>A::,C21orf58:NM_001286463.1:intron_variant:MODIFIER:intron1/6:c.-259+76C>A::,C21orf58:NM_001286476.1:intron_variant:MODIFIER:intron2/8:c.-260+76C>A::,C21orf58:NM_001286477.1:intron_variant:MODIFIER:intron2/7:c.-179+76C>A::,C21orf58:NM_058180.5:intron_variant:MODIFIER:intron2/7:c.309+76C>A::											-0.0850			0.18,0.28	13.98								0				0	0	0 / 0							C21ORF58 (inh=n/a oe_syn=1.23 oe_mis=0.92 oe_lof=1.15)								
